Ovarian Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 or older who are able to understand the study procedures and are willing to give written consent to participate.
- People who have been diagnosed with a specific type of ovarian cancer (non-mucinous, high-grade epithelial ovarian cancer — either serous or endometrioid type) that is at an advanced stage (Stage III or IV, based on standard medical staging).
- People with Stage IV ovarian cancer, regardless of whether surgery was performed, was not possible, or whether chemotherapy before surgery is planned.
- People with Stage III ovarian cancer, including those who had surgery with or without remaining disease, those whose cancer could not be operated on, or those who received chemotherapy before surgery.
- A stored tumour tissue sample (from a previous biopsy or surgery) must be available for laboratory analysis.
- People who could become pregnant must have a negative pregnancy test (blood or urine) within 72 hours before starting the study treatment.
- People who could become pregnant must be willing to use highly effective contraception, or agree to abstain from activities that could lead to pregnancy, from the start of the study until 180 days after the last dose of treatment. Alternatively, people who are post-menopausal (no periods for more than 1 year) or have been surgically sterilised also meet this criterion.
- Kidney and liver function test results must fall within acceptable ranges, as defined by standard laboratory measures (confirm with trial site for specific values).
- People who have a general health/activity level rated as fully active or restricted only in physically strenuous activity (this is measured using a standard scale called the ECOG score of 0 or 1).
- People who have normal blood pressure, or whose high blood pressure is being well managed with treatment.
- People who are able to swallow and take oral (by mouth) medication.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian cancer is of a specific tumour type: mucinous, germ cell, transitional cell, or undifferentiated.
- People who have low-grade or Grade 1 epithelial ovarian cancer.
- People who have a medical condition, ongoing treatment, or abnormal lab results that, in the opinion of the study doctor, could interfere with the study results or with the person completing the full course of the study.
- People who are pregnant, planning to become pregnant during the study or within 180 days after the last dose, or who are breastfeeding or planning to breastfeed within 30 days of the final dose.
- People who have a current or past diagnosis of certain blood-related bone marrow conditions known as MDS (myelodysplastic syndrome) or AML (acute myeloid leukaemia).
- People who have a known allergy or sensitivity to the active ingredient of the study drug or any of its components, including a yellow food dye called tartrazine.
- People who have high blood pressure that has not been adequately treated or controlled (specifically, a top number above 140 or a bottom number above 90 on a blood pressure reading).
- People who have a past history of a rare brain condition involving swelling and abnormal brain activity, known as PRES (Posterior Reversible Encephalopathy Syndrome).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Safety and tolerability.; PFS measured from the time of the first dose of niraparib.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.